Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesenchymal stem cell therapy (HepaStem) - Cellaion

Next Previous
X
Search
Drug Profile

Mesenchymal stem cell therapy (HepaStem) - Cellaion

Alternative Names: hALDMSC - Cellaion; HepaStem; Heterologous Human Adult Liver derived Progenitor Cells; HHALPC; human Adult Liver-Derived Mesenchymal Progenitor/Stem Cells - Cellaion

Latest Information Update: 28 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catholic University of Louvain
  • Developer Cellaion; LifeLiver; Promethera Biosciences
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crigler-Najjar syndrome; Inborn urea cycle disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Inborn urea cycle disorders
  • Phase II Liver failure
  • Phase I/II Crigler-Najjar syndrome; Non-alcoholic steatohepatitis
  • No development reported Haemophilia; Hepatic fibrosis
  • Discontinued Glycogen storage disease type I; Phenylketonuria

Most Recent Events

  • 24 May 2024 Cellaion terminates a phase IIb HEP102-DHELIVER trial in Liver failure in Bulgaria, Germany, Latvia, Lithuania, the UK, Denmark, Portugal, Spain, Netherlands, Estonia, Austria, Slovenia and Belgium due to sponsor's decision (NCT04229901)
  • 21 Jun 2023 Efficacy and pharmacodynamics data from phase I/II PANASH trial were presented at the European Association for the Study of the Liver Congress (EASL-2023)
  • 28 Dec 2020 No recent reports of development identified for research development in Haemophilia in Belgium (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top